image du produit
Lancet Infectious Diseases, The

S'abonner

The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later - 27/03/20

Doi : 10.1016/S1473-3099(20)30003-7 
Ramanan Laxminarayan, PhD a, b, ⁎ , Thomas Van Boeckel c, Isabel Frost, DPhil a, d, Samuel Kariuki, ProfPhD e, Ejaz Ahmed Khan, ProfMBBS f, Direk Limmathurotsakul, PhD g, D G Joakim Larsson, ProfPhD h, Gabriel Levy-Hara, ProfMD i, Marc Mendelson, ProfPhD j, Kevin Outterson, LLM k, Sharon J Peacock, ProfPhD l, Yong-Guan Zhu, ProfPhD m
a Centre for Disease Dynamics, Economics & Policy, New Delhi, India 
b Princeton Environmental Institute, Princeton University, Princeton, NJ, USA 
c Institute for Environmental Decisions, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland 
d Faculty of Medicine, Department of Infectious Disease, Imperial College, London, UK 
e Kenya Medical Research Institute, Nairobi, Kenya 
f Shifa International Hospital, Shifa Tameer-e-Millat University, Islamabad, Pakistan 
g Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand 
h Institute for Biomedicine, Department of Infectious Diseases, Centre for Antibiotic Resistance Research, University of Gothenburg, Gothenburg, Sweden 
i Infectious Disease Unit, Hospital Carlos G Durand, Buenos Aires, Argentina 
j Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa 
k School of Law, Boston University, Boston, MA, USA 
l Department of Medicine, University of Cambridge, Cambridge, UK 
m State Key Lab of Urban and Regional Ecology, Research Centre for Eco-environmental Sciences, Chinese Academy of Sciences, Beijing, China 

* Correspondence to: Dr Ramanan Laxminarayan, Centre for Disease Dynamics, Economics, and Policy, New Delhi 110020, India Centre for Disease Dynamics, Economics, and Policy New Delhi 110020 India

Summary

In 2013, a Lancet Infectious Diseases Commission described the state of antimicrobial resistance worldwide. Since then, greater awareness of the public health ramifications of antimicrobial resistance has led to national actions and global initiatives, including a resolution at the high-level meeting of the UN General Assembly in 2016. Progress in addressing this issue has ranged from a ban on irrational drug combinations in India to commitments to ban colistin as a growth promoter in animals, improve hospital infection control, and implement better antimicrobial stewardship. Funds have been mobilised, and regulatory barriers to new antibiotic development have been relaxed. These efforts have been episodic and uneven across countries, however. Sustained funding for antimicrobial resistance and globally harmonised targets to monitor progress are still urgently needed. Except for in a few leading countries, antimicrobial resistance has not captured the sustained focus of national leaders and country-level actors, including care providers.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 20 - N° 4

P. e51-e60 - avril 2020 Retour au numéro
Article précédent Article précédent
  • Correction to Lancet Infect Dis 2020; published online Feb 11. https://doi.org/10.1016/S1473-3099(20)30003-7
| Article suivant Article suivant
  • Researching Zika in pregnancy: lessons for global preparedness
  • A E Ades, Claire Thorne, Antoni Soriano-Arandes, Catherine S Peckham, David W Brown, Daniel Lang, J Glenn Morris, Celia D C Christie, Carlo Giaquinto

Déjà abonné à cette revue ?